Abbott is FDA approved for Tendyne™ to strengthen its minimally invasive cardiac portfolio

Abbott Institute (NYSE:abt) FDA approval for the Tendyne™ Transcatheter Mitral Valve Lepractement (TMVR) system is the first device of its kind approved in the United States to treat mitral valve disease without heart surgery.

Tendyne is specifically designed for patients who are not suitable candidates for repair or replacement of surgical valves. This product perfectly fits the trends of an aging population and the demand for less invasive treatments, meaning it could become a critical cash cow for ABT.

An operating room with a doctor monitoring a patient’s vital signs during surgery using medical equipment.

This approval gives Abbott Laboratories (NYSE: ABT) a competitive advantage in the growing structural heart market, worth around $15 billion worldwide, potentially accelerating the company’s growth. The Medical Devices segment accounted for 47% of total revenue for the first quarter 2025, making it the fastest growing segment. US revenues recorded a 15% growth. In other words, this segment is already at the heart of the growth story.

The announcement comes a few weeks after ABT repeated its 2025 organic revenue growth guidance at 7.5% to 8.5%, but the street consensus only predicts total revenue growth. This could increase the likelihood of positive surprises later this year, and bring ABT stocks to even higher. For reference, ABT has already surpassed the broad market at a massive 17% of 17% per year, highlighting its strong momentum.

Abbott Laboratories (NYSE: ABT) is a global healthcare company that owns a portfolio of life-changing technologies across diagnostics, medical devices, nutritional and branded generic drugs.

While we acknowledge the potential of ABT as an investment, our conviction lies in the belief that some AI stocks hold a greater promise to offer higher returns and limited downside risk. If you’re looking for AI stocks that are more promising than ABT and have a potential of 100 times upside, check out our report on this Cheapest AI stocks.

Read next: 12 Most Popular Stocks on Robin Hood in 2025 and 11 Global Stocks for Sale to Buy According to Hedge Funds

Disclosure: None.